Gutiérrez-Leonard H, Martínez-Lara E, Fierro-Macías A E, Mena-Burciaga V M, Ronquillo-Sánchez M D, Floriano-Sánchez E, Cárdenas-Rodríguez N
Interventional Cardiology Laboratory, Hospital Central Militar, Secretaría de la Defensa Nacional, 11649, Mexico City, Mexico.
Multidisciplinary Research Laboratory, Escuela Militar de Graduados de Sanidad, Secretaría de la Defensa Nacional, 11200, Mexico City, Mexico.
Ir J Med Sci. 2017 Aug;186(3):597-605. doi: 10.1007/s11845-016-1515-6. Epub 2016 Oct 11.
Cardiovascular disease is the leading cause of death in the Western world, and a major cause of this disease is atherosclerosis. Research has demonstrated that pregnancy-associated plasma protein A (PAPP-A) plays a role in cardiovascular disease, as evidenced by the association between PAPP-A and severity of heart damage.
The aim of this work was to investigate the correlation between PAPP-A concentrations in coronary and peripheral blood and certain clinicopathological factors and antioxidant enzyme activities in patients diagnosed with coronary artery disease.
For 65 patients, arterial blood was obtained by puncturing the femoral or radial artery, and coronary blood was obtained via percutaneous coronary intervention. PAPP-A, catalase (CAT), superoxide dismutase-1 (SOD-1), and superoxide dismutase-2 (SOD-2) levels were measured using spectrometric methods.
Coronary PAPP-A levels were slightly higher than peripheral PAPP-A levels (81.25 ± 2.34 and 62 ± 3 ng/mL, respectively, P < 0.0001); these levels were correlated with each other (r = 0.6629, P < 0.001) but not with clinicopathological factors (P > 0.05). Coronary PAPP-A levels were significantly elevated among patients at risk for cardiovascular disease (P < 0.05). Antioxidant enzyme activities were significantly higher in coronary samples than in peripheral samples from subjects with ischemic cardiopathy secondary to atherosclerosis (P < 0.001). Neither coronary nor peripheral PAPP-A levels were correlated with antioxidant enzyme activities in patients with cardiopathy secondary to atherosclerosis (P > 0.05).
PAPP-A levels could be used as biomarkers to identify patients at risk of coronary artery disease.
心血管疾病是西方世界的主要死因，而动脉粥样硬化是这种疾病的主要病因。研究表明，妊娠相关血浆蛋白A（PAPP-A）在心血管疾病中起作用，PAPP-A与心脏损伤严重程度之间的关联证明了这一点。
本研究旨在探讨冠心病患者冠状动脉血和外周血中PAPP-A浓度与某些临床病理因素及抗氧化酶活性之间的相关性。
对65例患者，通过穿刺股动脉或桡动脉获取动脉血，通过经皮冠状动脉介入获取冠状动脉血。采用光谱法测定PAPP-A、过氧化氢酶（CAT）、超氧化物歧化酶-1（SOD-1）和超氧化物歧化酶-2（SOD-2）水平。
冠状动脉PAPP-A水平略高于外周血PAPP-A水平（分别为81.25±2.34和62±3 ng/mL，P<0.0001）；这些水平相互相关（r=0.6629，P<0.001），但与临床病理因素无关（P>0.05）。心血管疾病风险患者的冠状动脉PAPP-A水平显著升高（P<0.05）。在动脉粥样硬化继发缺血性心脏病患者中，冠状动脉样本中的抗氧化酶活性显著高于外周样本（P<0.001）。在动脉粥样硬化继发心脏病患者中，冠状动脉和外周血PAPP-A水平均与抗氧化酶活性无关（P>0.05）。
PAPP-A水平可作为识别冠状动脉疾病风险患者的生物标志物。
